361 related articles for article (PubMed ID: 35029811)
1. An Update on Psychopharmacological Treatment of Autism Spectrum Disorder.
Aishworiya R; Valica T; Hagerman R; Restrepo B
Neurotherapeutics; 2022 Jan; 19(1):248-262. PubMed ID: 35029811
[TBL] [Abstract][Full Text] [Related]
2. An Update on Psychopharmacological Treatment of Autism Spectrum Disorder.
Aishworiya R; Valica T; Hagerman R; Restrepo B
Focus (Am Psychiatr Publ); 2024 Apr; 22(2):198-211. PubMed ID: 38680976
[TBL] [Abstract][Full Text] [Related]
3. Emerging pharmacological therapies in fragile X syndrome and autism.
Yamasue H; Aran A; Berry-Kravis E
Curr Opin Neurol; 2019 Aug; 32(4):635-640. PubMed ID: 31045620
[TBL] [Abstract][Full Text] [Related]
4. Psychopharmacological interventions in autism spectrum disorder.
Accordino RE; Kidd C; Politte LC; Henry CA; McDougle CJ
Expert Opin Pharmacother; 2016; 17(7):937-52. PubMed ID: 26891879
[TBL] [Abstract][Full Text] [Related]
5. Autism Spectrum Disorder in Fragile X Syndrome: Cooccurring Conditions and Current Treatment.
Kaufmann WE; Kidd SA; Andrews HF; Budimirovic DB; Esler A; Haas-Givler B; Stackhouse T; Riley C; Peacock G; Sherman SL; Brown WT; Berry-Kravis E
Pediatrics; 2017 Jun; 139(Suppl 3):S194-S206. PubMed ID: 28814540
[TBL] [Abstract][Full Text] [Related]
6. Melatonin as a Novel Interventional Candidate for Fragile X Syndrome with Autism Spectrum Disorder in Humans.
Won J; Jin Y; Choi J; Park S; Lee TH; Lee SR; Chang KT; Hong Y
Int J Mol Sci; 2017 Jun; 18(6):. PubMed ID: 28632163
[TBL] [Abstract][Full Text] [Related]
7. Current knowledge, challenges, new perspectives of the study, and treatments of Autism Spectrum Disorder.
Lotufo Denucci B; Silva de Lima L; Ferreira Lima Mota I; Rocha Madureira Azevedo J; Germino Veras L; Montenegro Luzardo Bicca JV; de Miranda Santana B; Beserra Pinheiro G; Gonçalves Coelho G; Mortari MR
Reprod Toxicol; 2021 Dec; 106():82-93. PubMed ID: 34695561
[TBL] [Abstract][Full Text] [Related]
8. Autism Spectrum Disorder: Classification, diagnosis and therapy.
Sharma SR; Gonda X; Tarazi FI
Pharmacol Ther; 2018 Oct; 190():91-104. PubMed ID: 29763648
[TBL] [Abstract][Full Text] [Related]
9. Double Genetic Hit: Fragile X Syndrome and Partial Deletion of Protein Patched Homolog 1 Antisense as Cause of Severe Autism Spectrum Disorder.
Saldarriaga W; Payán-Gómez C; González-Teshima LY; Rosa L; Tassone F; Hagerman RJ
J Dev Behav Pediatr; 2020 Dec; 41(9):724-728. PubMed ID: 32947579
[TBL] [Abstract][Full Text] [Related]
10. Overlapping Molecular Pathways Leading to Autism Spectrum Disorders, Fragile X Syndrome, and Targeted Treatments.
Salcedo-Arellano MJ; Cabal-Herrera AM; Punatar RH; Clark CJ; Romney CA; Hagerman RJ
Neurotherapeutics; 2021 Jan; 18(1):265-283. PubMed ID: 33215285
[TBL] [Abstract][Full Text] [Related]
11. Autism Symptoms in Fragile X Syndrome.
Niu M; Han Y; Dy ABC; Du J; Jin H; Qin J; Zhang J; Li Q; Hagerman RJ
J Child Neurol; 2017 Sep; 32(10):903-909. PubMed ID: 28617074
[TBL] [Abstract][Full Text] [Related]
12. Brief Report: Autism Symptoms in Infants with Fragile X Syndrome.
Roberts JE; Tonnsen BL; McCary LM; Caravella KE; Shinkareva SV
J Autism Dev Disord; 2016 Dec; 46(12):3830-3837. PubMed ID: 27628938
[TBL] [Abstract][Full Text] [Related]
13. The psychopharmacology of autism spectrum disorder and Rett syndrome.
Persico AM; Ricciardello A; Cucinotta F
Handb Clin Neurol; 2019; 165():391-414. PubMed ID: 31727226
[TBL] [Abstract][Full Text] [Related]
14. TARGETED TREATMENTS IN AUTISM AND FRAGILE X SYNDROME.
Gürkan CK; Hagerman RJ
Res Autism Spectr Disord; 2012 Oct; 6(4):1311-1320. PubMed ID: 23162607
[TBL] [Abstract][Full Text] [Related]
15. Novel mechanisms and treatment approaches in autism spectrum disorder.
Brian J; Doyle-Thomas K; Baribeau D; Anagnostou E
Discov Med; 2016 Aug; 22(119):47-54. PubMed ID: 27585230
[TBL] [Abstract][Full Text] [Related]
16. Multiple Antipsychotic Medication Use in Autism Spectrum Disorder.
Wink LK; Pedapati EV; Horn PS; McDougle CJ; Erickson CA
J Child Adolesc Psychopharmacol; 2017 Feb; 27(1):91-94. PubMed ID: 26465194
[TBL] [Abstract][Full Text] [Related]
17. Deciphering the roles of glycogen synthase kinase 3 (GSK3) in the treatment of autism spectrum disorder and related syndromes.
Rizk M; Saker Z; Harati H; Fares Y; Bahmad HF; Nabha S
Mol Biol Rep; 2021 Mar; 48(3):2669-2686. PubMed ID: 33650079
[TBL] [Abstract][Full Text] [Related]
18. A review of the use of psychotropic medication to address challenging behaviour in neurodevelopmental disorders.
Valdovinos MG; Epperson C; Johnson C
Int Rev Neurobiol; 2023; 173():43-65. PubMed ID: 37993179
[TBL] [Abstract][Full Text] [Related]
19. Psychopharmacological treatments in Down syndrome and autism spectrum disorder: State of the research and practical considerations.
Baumer NT; Capone G
Am J Med Genet C Semin Med Genet; 2023 Dec; 193(4):e32069. PubMed ID: 37870763
[TBL] [Abstract][Full Text] [Related]
20. Mood Stabilizers in Children and Adolescents With Autism Spectrum Disorders.
Canitano R
Clin Neuropharmacol; 2015; 38(5):177-82. PubMed ID: 26366961
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
